November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

Tirzepatide Significantly Reduces BMI in Adolescents With Obesity, Phase III Trial Shows

🏥 Public Health 2 min read 👁 5

A new phase III clinical trial indicates that once-weekly tirzepatide, paired with lifestyle interventions, substantially lowers body mass index in adolescents with obesity.

Tirzepatide Significantly Reduces BMI in Adolescents With Obesity, Phase III Trial Shows🏥Public Health

Photo: medpagetoday.com

Key points

  • Tirzepatide led to an 18.5% mean BMI reduction at week 72 compared to a 0.5% increase for placebo.
  • Over half of the participants on the medication no longer met the clinical threshold for obesity.
  • The study enrolled 160 adolescents aged 12 to 17 across multiple international research centers.

Adolescents with obesity or overweight accompanied by related medical complications experienced significant reductions in body mass index (BMI) when treated with once-weekly tirzepatide (Zepbound) alongside a healthy lifestyle intervention, according to the phase III SURMOUNT-ADOLESCENTS trial. Presented at the ObesityWeek annual meeting and published in JAMA, the study evaluated 160 participants between the ages of 12 and under 18 across 31 medical centers in countries including the U.S., Canada, Italy, and Poland.

By week 72, participants receiving tirzepatide achieved an average BMI reduction of 18.5%, compared with a 0.5% increase in the placebo group. Furthermore, 48.1% of those on the medication reached at least a 20% reduction in BMI, and over half (53.5%) no longer met the clinical threshold for obesity. Aaron S. Kelly, PhD, of the University of Minnesota Medical School, and colleagues reported that all ten key secondary outcomes also favored the treatment, including improvements in waist circumference, body weight, and physical functioning.

Editorialists led by William Heerman, MD, MPH, of Vanderbilt Health noted that while these results expand the therapeutic possibilities for pediatric obesity, clinicians should carefully individualize dose titration based on patient response, nutritional adequacy, and side effects rather than reflexively escalating to the maximum tolerated dose.

What to know: The double-blind trial followed participants for 72 weeks with subcutaneous injections. Always consult a qualified healthcare provider for personal medical decisions and treatment options.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/obesityweek/123891 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.